ClinicalTrials.gg
RecruitingNCT07225660HOLIDAYUpdated Mar 2, 2026

Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)

An interventional study of OCP pause in Fertility Preservation, sponsored by Shady Grove Fertility Reproductive Science Center. Recruiting at 3 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Shady Grove Fertility Reproductive Science Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

HOLIDAY is a two-arm, parallel-group, multi-center, randomized trial in which subjects undergoing planned oocyte cryopreservation will be randomized to receive either a 2-month pause of Combined Hormonal Contraceptives (CHC) or immediate start (without a pause).

Read the detailed description

Reproductive aging in women is a continuous process that begins prior to birth and extends until menopause. The primary mechanism behind this process is the depletion of the ovarian pool of non-growing follicles (NGFs). Previous models, such as the biphasic-exponential model, have postulated that female fertility prominently declines with age, significantly after age 32, and with a more accelerated rate after age 35. Newer models of ovarian follicular depletion predict no sudden change in decay rate but rather a constantly, increasing rate.

With the advent of vitrification, oocyte cryopreservation has become a powerful tool to help preserve female fertility potential against anticipated gamete exhaustion. At the same time, as more women choose to delay childbearing for various reasons, planned oocyte preservation is increasing in popularity. Continued optimization of protocols has led to improved outcomes with good oocyte yields. For women undergoing oocyte cryopreservation who are not actively attempting to conceive, endometrial development does not need to be synchronized with the oocytes. Thus, ovarian stimulation can be initiated irrespective of the phase of the menstrual cycle without adversely impacting oocyte yield or quality, thereby facilitating scheduling and reducing delays.

Many patients are utilizing combined hormonal contraception (CHC) at the time of their initial oocyte cryopreservation consultation. In the United States, about 14% of women aged 15-49 were using oral contraceptive pills (OCPs) in 2017-2019. While a short course of CHC exposure is unlikely to be detrimental to oocyte yield, longer-term CHC use may lead to significant suppression of the hypothalamic-pituitary-ovarian axis, gonadotropins, and in turn, follicular development. After only 3 months of CHC use, studies have demonstrated that the pituitary response to gonadotropin-releasing hormone is blunted. If hypothalamic-pituitary suppression from CHC prevents progression of follicle development to the antral stage, prolonged use may also lower the number of follicles susceptible to exogenous gonadotropin stimulation for oocyte collection and therefore total oocyte yield. Patients may require additional cycles and incur additional expense to achieve the desired number of cryopreserved oocytes.

It has been well demonstrated that markers of ORT, specifically, antral follicle count (AFC) and Anti-Müllerian hormone (AMH) are good predictors of oocyte yield. Existing evidence suggests that CHC use can suppress and diminish these measures of ovarian reserve by 20-30% via suppression of follicle-stimulating hormone (FSH). One study found that that long-term CHC user could increase AMH by 53% and AFC by 41%, with values returning to normal within 2 months and a plateau effect thereafter. Similarly, another study found after stopping long-term CHC use for 2 months, there was an average increase in AFC of 4.

Overall, existing literature regarding the association between hormonal contraceptive use and AMH concentration has historically been inconsistent but more recent data with large sample sizes, including a systematic review, concluded that AMH levels in women using CHC more than 6 months appears to markedly decline with recovery after discontinuation. Reproductive-age women with lower AMH percentiles at baseline may experience a greater suppressive effect from prolonged CHC use, while it is speculated that those with higher AMH percentiles at baseline may experience a lesser suppressive effect.

There are abundant observational data suggesting long-term CHC use is associated with reversable suppression of ovarian reserve markers, with biologic plausibility that this in turn may mask the "true biological potential" of the ovaries and possibly result in suboptimal oocyte yield. However, to date there are no published adequately powered prospective randomized data evaluating whether a contraceptive pause would lead to improved outcomes. Such practices may already be taking place in ART centers. The simple act of waiting for the potential of more oocytes takes on an obvious, low-risk appeal. Therefore, the investigators propose this assessor-blind, randomized clinical trial comparing a 2-month contraceptive pause to immediate oocyte cryopreservation, with oocyte yield as the primary outcome.

02

Conditions studied

  • Fertility Preservation

Keywords

  • planned oocyte cryopreservation
03

In context

Lead sponsor

Shady Grove Fertility Reproductive Science Center is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ovary-bearing individuals 18 to 40 years of age.
  2. \< 40 kg/m2
  3. Non-smoker for at least 3 months prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  1. greater than or equal to 40 kg/m2
  2. Current Smoker
  3. Any to ovarian stimulation or outpatient egg retrieval under anesthesia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
394 participants (estimated)

Study arms

  • Other
    Holiday

    Patients will undergo a 2 month drug holiday (pause) with combined hormonal contraceptives prior to planned oocyte cryopreservation

    Other: OCP pause

  • No intervention
    Immediate Start

    Patients will immediately begin planned oocyte cryopreservation after discontinuation of prolonged combined hormonal contraceptive

Interventions

  • OtherOCP pause

    Subjects in the study arm will be asked to discontinue combined hormonal contraceptives (CHC) for 2 months prior to planned oocyte cryopreservation

06

What researchers measure

Primary outcomes

  1. Oocyte maturation rate

    Median number of percentage of vitrified MII oocytes yielded per cycle

    Time frame: During oocyte retrieval

  2. Number of oocytes retrieved

    The median number of cumulus-oocyte complexes (COC) retrieved during oocyte retrieval

    Time frame: During oocyte retrieval

Secondary outcomes

  1. AMH levels

    Differences in AMH levels from baseline to cycle start

    Time frame: AMH level differences from baseline to post-drug holiday (2 months)

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Cohen BL, Katz M. Further studies on pituitary and ovarian function in women receiving hormonal contraception. Contraception. 1981 Aug;24(2):159-72. doi: 10.1016/0010-7824(81)90089-5. PubMed 6794980 ↗
  • Wan LS, Ganguly M, Weiss G. Pituitary response to LHRH stimulation in women on oral contraceptives: a followup dose response study. Contraception. 1981 Sep;24(3):229-34. doi: 10.1016/0010-7824(81)90035-4. PubMed 6796328 ↗
  • Yu Ng EH, Chi Wai Chan C, Tang OS, Shu Biu Yeung W, Chung Ho P. Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation. Hum Reprod. 2004 Dec;19(12):2811-5. doi: 10.1093/humrep/deh500. Epub 2004 Sep 9. PubMed 15358718 ↗
  • Tran ND, Aghajanova L, Kao CN, Cedars MI, Rosen MP. Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation. Fertil Steril. 2016 Mar;105(3):690-696. doi: 10.1016/j.fertnstert.2015.11.033. Epub 2015 Dec 13. PubMed 26696299 ↗
  • Cohen BL, Katz M. Pituitary and ovarian function in women receiving hormonal contraception. Contraception. 1979 Nov;20(5):475-87. doi: 10.1016/0010-7824(79)90053-2. PubMed 393456 ↗
  • Daniels K, Abma JC. Current Contraceptive Status Among Women Aged 15-49: United States, 2017-2019. NCHS Data Brief. 2020 Oct;(388):1-8. PubMed 33151146 ↗
  • Schattman GL. Cryopreservation of Oocytes. Author replies. N Engl J Med. 2016 Jan 21;374(3):288. doi: 10.1056/NEJMc1515128. No abstract available. PubMed 26789885 ↗
  • Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril. 2016 Feb;105(2):459-66.e2. doi: 10.1016/j.fertnstert.2015.10.026. Epub 2015 Nov 18. PubMed 26604065 ↗
  • Cil AP, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril. 2013 Aug;100(2):492-9.e3. doi: 10.1016/j.fertnstert.2013.04.023. Epub 2013 May 24. PubMed 23706339 ↗
  • Mesen TB, Mersereau JE, Kane JB, Steiner AZ. Optimal timing for elective egg freezing. Fertil Steril. 2015 Jun;103(6):1551-6.e1-4. doi: 10.1016/j.fertnstert.2015.03.002. Epub 2015 Apr 14. PubMed 25881876 ↗
  • Rudick B, Opper N, Paulson R, Bendikson K, Chung K. The status of oocyte cryopreservation in the United States. Fertil Steril. 2010 Dec;94(7):2642-6. doi: 10.1016/j.fertnstert.2010.04.079. Epub 2010 Jun 18. PubMed 20723535 ↗
  • Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009 Jun;18(6):769-76. doi: 10.1016/s1472-6483(10)60025-9. PubMed 19490780 ↗
  • Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod. 2008 Mar;23(3):699-708. doi: 10.1093/humrep/dem408. Epub 2008 Jan 11. PubMed 18192670 ↗
  • Sozou PD, Hartshorne GM. Time to pregnancy: a computational method for using the duration of non-conception for predicting conception. PLoS One. 2012;7(10):e46544. doi: 10.1371/journal.pone.0046544. Epub 2012 Oct 4. PubMed 23056338 ↗
  • Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol. 2004 Jan;103(1):51-6. doi: 10.1097/01.AOG.0000100153.24061.45. PubMed 14704244 ↗
  • Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992 Nov;7(10):1342-6. doi: 10.1093/oxfordjournals.humrep.a137570. PubMed 1291557 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2025
First posted
Nov 10, 2025
StartActual
Feb 25, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225660
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Collaborators
EMD Serono
Responsible party
Kate Devine (Medical Director and Chief Research Officer, USFertility, Shady Grove Fertility Reproductive Science Center) — Principal investigator
First posted
Nov 10, 2025
Start date
Feb 25, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Tasha Newsome, Clinical Research Supervisor
Contact
Tasha.Newsome@sgfertility.com
301-545-1289
Seth J Barishansky, MD
Contact
HolidayStudy@USFertility.com
475-267-9469

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion